Literature DB >> 18384420

Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): measuring satisfaction with acute migraine treatment in clinical trials.

M Kimel1, R Hsieh, J McCormack, S P Burch, D A Revicki.   

Abstract

This study was aimed to evaluate in clinical trial settings the psychometric properties of the revised Patient Perception of Migraine Questionnaire (PPMQ-R), a satisfaction measure for acute migraine treatment. The PPMQ-R was administered 24 h post dosing in 1304 migraineurs randomized to two identical Phase 3, single-attack trials. Reliability, concurrent and construct validity and known-groups validity were evaluated using Cronbach's alpha, Pearson correlations and analysis of variance, respectively. PPMQ-R scale and Total scores (Efficacy, Functionality and Ease of use) showed very good internal consistency reliability (alpha 0.84-0.99). Efficacy, Functionality and Total PPMQ-R scores showed large, inverse relationships with migraine pain severity, number of migraine symptoms and work ability (r = -0.62 to -0.75; all P < 0.0001). All scales discriminated among migraine pain severity levels (all P < 0.001). The PPMQ-R has sufficient evidence of validity and reliability for measuring patient satisfaction, an important benchmark of quality and effective care.

Entities:  

Mesh:

Year:  2008        PMID: 18384420     DOI: 10.1111/j.1468-2982.2007.01524.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  10 in total

1.  Sumatriptan/naproxen sodium combination versus its components administered concomitantly for the acute treatment of migraine: a pragmatic, crossover, open-label outcomes study.

Authors:  Stephen Landy; Rebecca Hoagland; Dakota Hoagland; Jane Saiers; Gena Reuss
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 2.  Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 3.  Difficulties in work-related activities among migraineurs are scarcely collected: results from a literature review.

Authors:  A Raggi; V Covelli; M Leonardi; L Grazzi; M Curone; D D'Amico
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

4.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Tolerability, and Safety of Celecoxib Oral Solution (ELYXYB) in Acute Treatment of Episodic Migraine with or without Aura.

Authors:  Richard B Lipton; Sagar Munjal; Stewart J Tepper; Charlie Iaconangelo; Daniel Serrano
Journal:  J Pain Res       Date:  2021-08-19       Impact factor: 3.133

5.  Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches.

Authors:  Sally Mannix; Anne Skalicky; Dawn C Buse; Pooja Desai; Sandhya Sapra; Brian Ortmeier; Katherine Widnell; Asha Hareendran
Journal:  Health Qual Life Outcomes       Date:  2016-10-06       Impact factor: 3.186

6.  Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).

Authors:  Merel L Kimman; Adrienne H Rotteveel; Marlies Wijsenbeek; Rémy Mostard; Nelleke C Tak; Xana van Jaarsveld; Marjolein Storm; Kioa L Wijnsma; Marielle Gelens; Nicole C A J van de Kar; Jack Wetzels; Carmen D Dirksen
Journal:  Patient       Date:  2017-10       Impact factor: 3.883

7.  Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs).

Authors:  Kirstie L Haywood; Tom S Mars; Rachel Potter; Shilpa Patel; Manjit Matharu; Martin Underwood
Journal:  Cephalalgia       Date:  2017-09-18       Impact factor: 6.292

8.  DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment.

Authors:  Richard B Lipton; Sagar Munjal; Elimor Brand-Schieber; Alan M Rapoport
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

9.  Development and validation of prescription drug risk, efficacy, and benefit perception measures in the context of direct-to-consumer prescription drug advertising.

Authors:  Bridget J Kelly; Douglas J Rupert; Kathryn J Aikin; Helen W Sullivan; Mihaela Johnson; Carla M Bann; Nicole Mack; Brian G Southwell; Sue West; Sarah Parvanta; Alexander Rabre; Susana Peinado
Journal:  Res Social Adm Pharm       Date:  2020-08-06

10.  Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms.

Authors:  Koonal K Shah; Bryan Bennett; Andrew Lenny; Louise Longworth; John E Brazier; Mark Oppe; A Simon Pickard; James W Shaw
Journal:  Eur J Health Econ       Date:  2021-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.